Company · pfizer-69d9f765

Pfizer

4 sourcescompanies-2026-11-14-0.1.0

Cite this record

ConductScience Library. Pfizer. Companies, record pfizer-69d9f765. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/pfizer-69d9f765

On this page

Company

The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.

Name: Pfizer
Trials: 4,920
As lead sponsor: 3,337
As collaborator: 1,583
Recruiting: 235
Active, recruiting or not: 440
Completed: 3,513
Stopped early, withdrawn or suspended: 783
Posted results: 2,183
Trials by phase: Phase 1 1,419, Phase 2 1,224, Phase 3 893, Phase 4 449
Drugs its trials test: 850
Comparisons calculated in its trials: 1,772
First trial registered: 2000-08-21
Last update: 2026-11-12

Source ClinicalTrials.gov

Pipeline850

The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.

Drug	Highest phase registered	Trials	As lead sponsor	Recruiting	Targets	Mechanism	In Drugs and targets	Source
PALBOCICLIB	Phase 4	151	58	11	CCND1, CDK4, CDK6	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	https://conductscience.org/library/drugs/CHEMBL189963	Open Targets
SUNITINIB	Phase 4	132	62	3	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	Macrophage colony stimulating factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor RET inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	https://conductscience.org/library/drugs/CHEMBL535	Open Targets
TOFACITINIB	Phase 4	117	103	3	JAK1, JAK2, JAK3, TYK2	Janus Kinase (JAK) inhibitor	https://conductscience.org/library/drugs/CHEMBL221959	Open Targets
VARENICLINE	Phase 4	88	43	0	CHRNA4, CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	https://conductscience.org/library/drugs/CHEMBL1076903	Open Targets
AZITHROMYCIN	Phase 4	69	57	0			https://conductscience.org/library/drugs/CHEMBL529	Open Targets
ATORVASTATIN	Phase 4	63	24	0	HMGCR	HMG-CoA reductase inhibitor	https://conductscience.org/library/drugs/CHEMBL1487	Open Targets
CRIZOTINIB	Phase 4	60	42	2	ALK, EML4, MET, MST1R, NPM1, ROS1	ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; Hepatocyte growth factor receptor inhibitor; Macrophage-stimulating protein receptor inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor	https://conductscience.org/library/drugs/CHEMBL601719	Open Targets
ETANERCEPT	Phase 4	57	51	0	TNF	TNF-alpha inhibitor	https://conductscience.org/library/drugs/CHEMBL1201572	Open Targets
MARAVIROC	Phase 4	54	2	0	CCR5	C-C chemokine receptor type 5 antagonist	https://conductscience.org/library/drugs/CHEMBL256907	Open Targets
SUNITINIB MALATE	Phase 4	49	23	0	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	Macrophage colony stimulating factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor RET inhibitor; Vascular endothelial growth factor receptor inhibitor	https://conductscience.org/library/drugs/CHEMBL1567	Open Targets

1 to 10 of 850

See all 850 pipeline

Trials4,920

The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.

Trial	Title	Role	Phase	Status	Type	Participants	Start	In Trials	Source
NCT07933848	A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment	Lead sponsor	Phase 1	Not yet recruiting	Interventional	24	2026-11-17	https://conductscience.org/library/trials/NCT07933848	ClinicalTrials.gov
NCT07933835	A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and Act in Healthy Adults.	Lead sponsor	Phase 1	Not yet recruiting	Interventional	82	2026-11-20	https://conductscience.org/library/trials/NCT07933835	ClinicalTrials.gov
NCT07932925	The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight	Lead sponsor	Phase 3	Not yet recruiting	Interventional	900	2026-11-17	https://conductscience.org/library/trials/NCT07932925	ClinicalTrials.gov
NCT07927023	A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma	Lead sponsor		Not yet recruiting	Observational	1	2026-11-09	https://conductscience.org/library/trials/NCT07927023	ClinicalTrials.gov
NCT07923981	A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors	Lead sponsor	Phase 3	Recruiting	Interventional	95	2026-10-23	https://conductscience.org/library/trials/NCT07923981	ClinicalTrials.gov
NCT07919678	A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)	Lead sponsor	Phase 3	Recruiting	Interventional	656	2026-10-26	https://conductscience.org/library/trials/NCT07919678	ClinicalTrials.gov
NCT07915609	A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)	Lead sponsor	Phase 3	Recruiting	Interventional	756	2026-10-26	https://conductscience.org/library/trials/NCT07915609	ClinicalTrials.gov
NCT07909122	Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer	Lead sponsor		Not yet recruiting	Observational	1	2026-10-30	https://conductscience.org/library/trials/NCT07909122	ClinicalTrials.gov
NCT07906262	Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations	Lead sponsor		Active, not recruiting	Observational	1	2026-10-12	https://conductscience.org/library/trials/NCT07906262	ClinicalTrials.gov
NCT07903415	A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.	Lead sponsor	Phase 1	Recruiting	Interventional	280	2026-10-29	https://conductscience.org/library/trials/NCT07903415	ClinicalTrials.gov

1 to 10 of 4,920

See all 4,920 trials

Conditions2,569

The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.

Condition	Trials
Healthy	391
Breast Cancer	120
Healthy Volunteers	100
Rheumatoid Arthritis	98
Breast Neoplasms	69
COVID-19	60
Healthy Participants	59
HIV Infections	58
Obesity	58
Smoking Cessation	58

1 to 10 of 2,569Source ClinicalTrials.gov

See all 2,569 conditions

Partners1,406

The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.

Organization	Class	Trials shared	In Companies	Source
Merck Sharp & Dohme LLC	Industry	71	https://conductscience.org/library/companies/merck-sharp-dohme-llc-d93bce8d	ClinicalTrials.gov
Bristol-Myers Squibb	Industry	70	https://conductscience.org/library/companies/bristol-myers-squibb-1255780f	ClinicalTrials.gov
ViiV Healthcare	Industry	41	https://conductscience.org/library/companies/viiv-healthcare-f2e841fd	ClinicalTrials.gov
Boehringer Ingelheim	Industry	40	https://conductscience.org/library/companies/boehringer-ingelheim-b8a070f5	ClinicalTrials.gov
Astellas Pharma Inc	Industry	36	https://conductscience.org/library/companies/astellas-pharma-inc-3611b895	ClinicalTrials.gov
Medivation, Inc.	Industry	34	https://conductscience.org/library/companies/medivation-inc-c494819f	ClinicalTrials.gov
Eli Lilly and Company	Industry	33	https://conductscience.org/library/companies/eli-lilly-and-company-fbcfeb1a	ClinicalTrials.gov
AstraZeneca	Industry	32	https://conductscience.org/library/companies/astrazeneca-0ba68854	ClinicalTrials.gov
Novartis	Industry	32	https://conductscience.org/library/companies/novartis-9328b082	ClinicalTrials.gov
Duke University	Other	30		ClinicalTrials.gov

1 to 10 of 1,406

See all 1,406 partners

Data dates

The date of each source this release read.

Sponsors and results posted: 2026-11-14; ClinicalTrials.gov
Trials' registrations: 2026-11-12; ClinicalTrials.gov
Drug links and targets: 2026-09-18; Open Targets
Comparisons: 2026-03-23; Trial comparisons

Sources 4

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL
ClinicalTrials.govNo license stated
Open TargetsCC0 1.0

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this company from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/companies/v1/pfizer-69d9f765

GET https://conductscience.org/api/companies/v1/pfizer-69d9f765/pipeline?page=2

API reference For AI assistants